XWELL reports FY 2024 revenue $33.9M (+13% YoY), net loss narrows to $16.9M

XWELL, Inc.

2025-Q1 EPS reported -$1.00 revenue$7,023,000

Revenue $33.9M (+13% YoY); gross margin rose to 26.3% from 12.2%.
Net loss attributable to XWELL narrowed to $16.9M from $27.7M in 2023.
CDC extended Traveler-based Genomic Surveillance Program for 3 years; base value $53.7M, ceiling $85.7M.
Closed $4M private placement in Jan 2025; plans to acquire medical spas in select metros in 2025.
Cash & equivalents $4.6M, marketable securities $7.3M, no long-term debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.